Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6,036 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Mini-BEAM is effective as a bridge to transplantation in patients with refractory or relapsed Hodgkin lymphoma who have failed to respond to previous lines of salvage chemotherapy but not in patients with salvage-refractory DLBCL.
Moore S, Kayani I, Peggs K, Qian W, Lowry L, Thomson K, Linch DC, Ardeshna K. Moore S, et al. Br J Haematol. 2012 Jun;157(5):543-52. doi: 10.1111/j.1365-2141.2012.09096.x. Epub 2012 Mar 20. Br J Haematol. 2012. PMID: 22429186 Free article.
An unusual case of myocardial infarction.
Moore S, Rabin N, Cavanagh J, Playford D, Yong K. Moore S, et al. BMJ Case Rep. 2010;2010:bcr11.2009.2422. doi: 10.1136/bcr.11.2009.2422. Epub 2010 Apr 5. BMJ Case Rep. 2010. PMID: 22479298 Free PMC article.
A new prognostic model for myeloma patients relapsing from upfront autologous transplantation based on ISS and PFS1.
Chavda SJ, Maciocia PM, Mesiri P, Counsell N, Kothari J, Bird A, Mariner C, Chew A, Clesham K, Moore S, Percy L, Rismani A, D'Sa S, Rabin N, Popat R, Yong K. Chavda SJ, et al. Among authors: moore s. Br J Haematol. 2019 Apr;185(2):350-353. doi: 10.1111/bjh.15487. Epub 2018 Jul 9. Br J Haematol. 2019. PMID: 29984833 Free article. No abstract available.
Bortezomib consolidation post-ASCT as frontline therapy for multiple myeloma deepens disease response and MRD-negative rate whilst maintaining QOL and response to re-treatment at relapse.
Cohen OC, Counsell N, Rabin N, Popat R, Owen RG, Popova B, Schofield O, Clifton-Hadley L, Lyons-Lewis J, Rawstron A, Spence C, de Tute RM, Hughes D, Moore S, Smith P, Yong KL. Cohen OC, et al. Among authors: moore s. Br J Haematol. 2019 Jun;185(5):948-951. doi: 10.1111/bjh.15649. Epub 2018 Nov 20. Br J Haematol. 2019. PMID: 30460696 Free article. No abstract available.
Clinical outcomes of bortezomib-based therapy in myeloma.
Djebbari F, Srinivasan A, Vallance G, Moore S, Kothari J, Ramasamy K. Djebbari F, et al. Among authors: moore s. PLoS One. 2018 Dec 12;13(12):e0208920. doi: 10.1371/journal.pone.0208920. eCollection 2018. PLoS One. 2018. PMID: 30540831 Free PMC article.
Carfilzomib therapy for relapsed myeloma: results of a UK multicentre experience.
Djebbari F, Hubenov H, Neelakantan P, Wolf J, Offer M, Khera A, Louka E, Vallance G, Kothari J, Moore S, Ramasamy K. Djebbari F, et al. Among authors: moore s. Br J Haematol. 2020 Feb;188(4):e57-e60. doi: 10.1111/bjh.16324. Epub 2019 Dec 2. Br J Haematol. 2020. PMID: 31792927 Free article. Clinical Trial. No abstract available.
6,036 results